It has demonstrated robust efficacy in human tumor xenografts, and combining STX-478 with other treatments such as fulvestrant and CDK4/6 inhibitors has provided durable tumor regression without substantial side effects (35). This evidence concerns the gene CDK4 and neoplasm.